bioAffinity Showcases CyPath Lung at Cleveland Clinic
SAN ANTONIO, Texas, United States, April 7, 2026 bioAffinity Technologies, Inc. announced that its CyPath® Lung diagnostic test will...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SAN ANTONIO, Texas, United States, April 7, 2026 bioAffinity Technologies, Inc. announced that its CyPath® Lung diagnostic test will...
SAN ANTONIO, TX, March 17, 2026 bioAffinity Technologies, Inc. has released a new clinical case study demonstrating how its...
FRANKLIN LAKES, N.J., Feb. 9, 2026 — Becton, Dickinson and Company (BD) announced the successful completion of the previously...
